<SEC-DOCUMENT>0001104659-21-024805.txt : 20210217
<SEC-HEADER>0001104659-21-024805.hdr.sgml : 20210217
<ACCEPTANCE-DATETIME>20210217154534
ACCESSION NUMBER:		0001104659-21-024805
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210216
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210217
DATE AS OF CHANGE:		20210217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEALTHEQUITY, INC.
		CENTRAL INDEX KEY:			0001428336
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36568
		FILM NUMBER:		21644508

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020
		BUSINESS PHONE:		801-727-1000

	MAIL ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHEQUITY INC
		DATE OF NAME CHANGE:	20080227
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm216328d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:hqy="http://healthequity.com/20210216">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_hqy_healthequity.com_20210216 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20210216_20210216 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001428336 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityCentralIndexKey">0001428336</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="hqy-20210216.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2021-02-16to2021-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001428336</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-16</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form <span id="xdx_900_edei--DocumentType_c20210216__20210216_zokuWNiV9S9h"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--DocumentPeriodEndDate_c20210216__20210216_zIMm1waXWdzc"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 16, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number<b>: <span id="xdx_90A_edei--EntityFileNumber_c20210216__20210216_zyPKvIOUELoi"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityFileNumber">001-36568</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20210216__20210216_zl4KzPiI0J7l"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityRegistrantName">HEALTHEQUITY,&#160;INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20210216__20210216_zRvGNhIcYWv"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_90D_edei--EntityFileNumber_c20210216__20210216_zqt8vFwl2mmj"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityFileNumber">001-36568</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20210216__20210216_zlHMRKlpn68e"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityTaxIdentificationNumber">52-2383166</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br /> incorporation or organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission)<br />
File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br /> Identification Number)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20210216__20210216_zfx7HIxLRwQ7"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityAddressAddressLine1">15 West Scenic Pointe Drive</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine2_c20210216__20210216_zHIeYG1lCYPh"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityAddressAddressLine2">Suite&#160;100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20210216__20210216_zrtmaqHDReS1"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityAddressCityOrTown">Draper</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20210216__20210216_zIu5kF6oW046"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20210216__20210216_zeMbmxrdL9b4"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:EntityAddressPostalZipCode">84020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20210216__20210216_zNM0To2hum8b"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:CityAreaCode">801</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20210216__20210216_zy0zYtRyVoh6"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:LocalPhoneNumber">727-1000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including Zip Code, and Telephone
Number, including Area Code, of Registrant&#146;s Principal Executive Offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.4pt"></td><td style="width: 12.6pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20210216__20210216_zjEmLVpoplB9"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.6pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20210216__20210216_zlXyad2QEsFl"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.6pt"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20210216__20210216_zBYKrYpV5jI9"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 12.6pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20210216__20210216_zI2ak8gpboi"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17
CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20210216__20210216_zWjkQ4lLcFgi"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 37%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 26%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20210216__20210216_zgvAuoiTHb67"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:Security12bTitle">Common stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--TradingSymbol_c20210216__20210216_zMJzuauf3q2b"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" name="dei:TradingSymbol">HQY</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SecurityExchangeName_c20210216__20210216_zHUqriCVtwA8"><ix:nonNumeric contextRef="From2021-02-16to2021-02-16" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 67pt"><span style="font-family: Times New Roman, Times, Serif"><b>Item 1.01</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Entry into a Definitive Material Agreement</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">On February 16, 2021, HealthEquity, Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
entered into an underwriting agreement (the &#8220;<span style="text-decoration: underline">Underwriting Agreement</span>&#8221;) with BofA Securities, Inc. (the &#8220;<span style="text-decoration: underline">Underwriter</span>&#8221;).
Pursuant to the terms of the Underwriting Agreement, the Company agreed to sell, and the Underwriter agreed to purchase, subject
to and on the conditions set forth therein, an aggregate of 5,000,000 shares of the Company&#8217;s common stock. The Company has
also granted the Underwriter an option to purchase up to an additional 750,000 shares of the Company&#8217;s common stock. The
Company estimates that the net proceeds from the offering will be approximately $397.0 million, or approximately $456.6 million
if the Underwriter exercise in full its option to purchase additional shares of the Company&#8217;s common stock after deducting
the estimated discount to the Underwriter and the estimated fees and expenses of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">The Underwriting Agreement contains customary representations,
warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters,
including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 34pt 0pt 0">The offering is being made pursuant to the Company&#8217;s
effective shelf registration statement on Form S-3 (Registration No. 333-227231), including the prospectus dated September 7, 2018
as supplemented by the prospectus supplement dated February 16, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 29pt 0pt 0">The Underwriting Agreement is filed as Exhibit 1.1
to this Current Report on Form 8-K and incorporated herein by reference. The above description is qualified in its entirety by
reference to such exhibit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9.01</b></span></td>
    <td colspan="2" style="padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="padding-left: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
    <td style="width: 3%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 131pt; width: 85%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 131pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><a href="tm216328d3_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm216328d3_ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated as of February 16, 2021, by and between HealthEquity, Inc. and BofA Securities, Inc.</a></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>104</td>
    <td>&#160;</td>
    <td> Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">HEALTHEQUITY, INC.</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Darcy Mott</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Darcy Mott</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Executive Vice President and Chief Financial Officer</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 17, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LppWRO2jRUWsIkXE19huJdhmyyb+HclbGlvEZWFZZr4ZIUKxoqWukeE0zzM4YNPWyiHkWCGjKdA70vUmAX9zvGjrWBnXvT8wJc+gZ8YDeS680Fnv2mKZgJwMR9EwmoGcJnEM+60IvnpKptIlGqdVDcqUsGdqWaNT/OoTDupJhppXV3VEtppMAtFA9vIbYhnFsKO7ehBfLWRZKoKwm0CsmG7tt+ZmHTWwqLHxXbZH/xt8AD1TSYE= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm216328d3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>Execution Version&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HEALTHEQUITY,&nbsp;INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5,000,000 Shares of Common Stock, par
value $0.0001 per share</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Underwriting Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February 16, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HealthEquity,&nbsp;Inc., a Delaware corporation
(the &#8220;<B>Company</B>&#8221;), proposes to issue and sell to BofA Securities, Inc. (the &#8220;<B>Underwriter</B>&#8221;)
an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share (&#8220;<B>Common Stock</B>&#8221;), of the Company
(the &#8220;<B>Underwritten Shares</B>&#8221;) and, at the option of the Underwriter, up to an additional 750,000 shares of Common
Stock of the Company (the &#8220;<B>Option Shares</B>&#8221;). The Underwritten Shares and the Option Shares are herein referred
to as the &#8220;<B>Shares</B>&#8221;. The shares of Common Stock of the Company to be outstanding after giving effect to the issuance
and sale of the Shares are referred to herein as the &#8220;<B>Stock</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby confirms its agreement
with the Underwriter concerning the purchase and sale of the Shares, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Registration
Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the
 &#8220;<B>Commission</B>&#8221;) under the Securities Act of 1933, as amended, and the rules and regulations of the
Commission thereunder (collectively, the &#8220;<B>Securities Act</B>&#8221;), an automatic shelf registration statement, as
defined in Rule 405 under the Securities Act, on Form S-3 (File No. 333-227231), including a related base prospectus dated
September&nbsp;7, 2018 (the &#8220;<B>Base Prospectus</B>&#8221;), relating to certain securities, including the Common Stock
and other securities that may be sold from time to time by the Company in accordance with Rule 415 of the Securities Act, and
such amendments thereof as may have been required to the date of this Agreement. The term &#8220;Registration
Statement&#8221; as used in this Agreement means the initial registration statement (including all exhibits, financial
schedules and all documents and information deemed to be a part of the registration statement by incorporation by reference
or otherwise, including pursuant to Rule 430B under the Securities Act), as amended at the time it became effective and as
supplemented or amended, including the information, if any, included or incorporated by reference in any preliminary
prospectus or the final prospectus filed with the Commission pursuant to Rule 424(b) and Rule 430B under the Securities Act.
If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the
 &#8220;<B>Rule 462 Registration Statement</B>&#8221;), then any reference herein to the term &#8220;Registration
Statement&#8221; shall be deemed to include such Rule 462 Registration Statement. The term &#8220;Preliminary
Prospectus&#8221; as used in this Agreement means the Base Prospectus and any preliminary prospectus supplement used or filed
with the Commission pursuant to Rule 424, in the form provided to the Underwriter by the Company for use in connection with
the offering of the Shares. The term &#8220;Prospectus&#8221; means the Base Prospectus, any Preliminary Prospectus and any
amendments or further supplements to such prospectus, and including, without limitation, the final prospectus supplement (the
 &#8220;<B>Prospectus Supplement</B>&#8221;) filed pursuant to and within the time limits described in Rule 424(b) with the
Commission in connection with the proposed issuance and sale of the Shares contemplated by this Agreement. Any reference in
this underwriting agreement (this &#8220;<B>Agreement</B>&#8221;) to the Registration Statement, any Preliminary Prospectus
or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12
of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary
Prospectus or the Prospectus, as the case may be, and any reference to &#8220;amend,&#8221; &#8220;amendment&#8221; or
 &#8220;supplement&#8221; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be
deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and
the rules and regulations of the Commission thereunder (collectively, the &#8220;<B>Exchange Act</B>&#8221;) that are deemed
to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such
terms in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the Applicable Time (as defined
below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the
 &#8220;<B>Pricing Disclosure Package</B>&#8221;): a Preliminary Prospectus dated February 16, 2021, a Prospectus dated February
16, 2021 and each &#8220;free-writing prospectus&#8221; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex
A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;<B>Applicable Time</B>&#8221; means
6:30 P.M., New York City time, on February 16, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Purchase of the Shares by the Underwriter.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company agrees to issue and sell the Underwritten Shares to the Underwriter as provided in this Agreement, and the Underwriter,
on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein,
agrees to purchase from the Company the number of Underwritten Shares set forth opposite the Underwriter&#8217;s name in Schedule
1 hereto at a purchase price per Share of $79.50 (the &#8220;<B>Purchase Price</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the Company agrees to issue
and sell the Option Shares to the Underwriter as provided in this Agreement, and the Underwriter, on the basis of the representations,
warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase from
the Company up to 750,000 Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions
declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Underwriter may exercise the option
to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date
of the Prospectus, by written notice to the Company. Such notice shall set forth the aggregate number of Option Shares as to which
the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same
date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth
full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance
with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the date and
time of delivery specified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company understands that the Underwriter intends to make a public offering of the Shares as soon after the effectiveness
of this Agreement as is, in the judgment of the Underwriter, advisable, and initially to offer the Shares on the terms set forth
in the Prospectus. The Company acknowledges and agrees that the Underwriter may offer and sell Shares to or through any affiliate
of the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Payment for the Shares shall be made by wire transfer in immediately available funds to the accounts specified by the Company
to the Underwriter in the case of the Underwritten Shares, at the offices of Latham &amp; Watkins LLP, counsel for the Underwriter,
at 885 Third Avenue, New York, New York 10022, at 9:00 A.M., New York City time, on February 19, 2021, or at such other time or
place on the same or such other date, not later than the fifth business day thereafter, as the Underwriter and the Company may
agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Underwriter
in the written notice of the Underwriter&#8217;s election to purchase such Option Shares. The time and date of such payment for
the Underwritten Shares is referred to herein as the &#8220;<B>Closing Date</B>&#8221;, and the time and date for such payment
for the Option Shares, if other than the Closing Date, is herein referred to as the &#8220;<B>Additional Closing Date</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be
made against delivery to the Underwriter of the Shares to be purchased on such date or the Additional Closing Date, as the case
may be, with any transfer taxes payable in connection with the issuance and sale of such Shares duly paid by the Company. Delivery
of the Shares shall be made through the facilities of The Depository Trust Company unless the Underwriter shall otherwise instruct.
The certificates for the Shares, if any, will be made available for inspection and packaging by the Underwriter at the office of
DTC or its designated custodian not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or
the Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company acknowledges and agrees that the Underwriter is acting solely in the capacity of an arm&#8217;s length contractual
counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining
the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally,
the Underwriter is not advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters
in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making
its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriter shall have no responsibility
or liability to the Company with respect thereto. Any review by the Underwriter of the Company, the transactions contemplated hereby
or other matters relating to such transactions will be performed solely for the benefit of the Underwriter and shall not be on
behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Preliminary Prospectus. </I>No order preventing or suspending the use of any Preliminary Prospectus has been issued by
the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied
in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company
makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information
relating to the Underwriter furnished to the Company in writing by the Underwriter expressly for use in any Preliminary Prospectus,
it being understood and agreed that the only such information furnished by the Underwriter consists of the information described
as such in Section&nbsp;7(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Pricing
Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as
of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation and
warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the
Underwriter furnished to the Company in writing by the Underwriter expressly for use in such Pricing Disclosure Package, it
being understood and agreed that the only such information furnished by the Underwriter consists of the information described
as such in Section&nbsp;7(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Issuer Free Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus,
the Company (including its agents and representatives, other than the Underwriter in its capacity as such) has not prepared, used,
authorized, approved or referred to and will not prepare, use, authorize, approve or refer to any &#8220;written communication&#8221;
(as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares
(each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i)
below) an &#8220;<B>Issuer Free Writing Prospectus</B>&#8221;) other than (i) any document not constituting a prospectus pursuant
to Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A
hereto, each electronic road show and any other written communications approved in writing in advance by the Underwriter. Each
such Issuer Free Writing Prospectus complied in all material respects with the Securities Act, has been or will be (within the
time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict
with the information included or incorporated by reference in the Registration Statement or the Pricing Disclosure Package, and,
when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus,
did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation and warranty with respect
to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and
in conformity with information relating to the Underwriter furnished to the Company in writing by the Underwriter expressly for
use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information
furnished by the Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. Each such Issuer Free Writing
Prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Shares
or until any earlier date that the Company notified or notifies the Underwriter as described in Section&nbsp;4(d), did not, does
not and will not include any information that conflicted, conflicts or will conflict with the information included or incorporated
by reference in the Registration Statement or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Registration
Statement and Prospectus. </I>The Registration Statement is an &#8220;automatic shelf registration statement&#8221; as
defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to
the date hereof; and no notice of objection of the Commission to the use of such registration statement or any post-effective
amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending
the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or
pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been
initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the
Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective
amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and
as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus complied and will comply in
all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <U>provided </U>that the Company makes no representation and
warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to the
Underwriter furnished to the Company in writing by the Underwriter expressly for use in the Registration Statement and the
Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished
by the Underwriter consists of the information described as such in Section&nbsp;7(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Incorporated Documents. </I>The documents incorporated by reference in the Registration Statement, the Prospectus and
the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements
of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and
any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure
Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange
Act and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Financial
Statements. </I>The historical financial statements (including the related notes thereto) of the Company and its consolidated
subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the
Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as
applicable, and present fairly in all material respects the historical financial position of the Company and its consolidated
subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the
periods specified; such historical financial statements have been prepared in conformity with generally accepted accounting
principles in the United States (&#8220;<B>GAAP</B>&#8221;) applied on a consistent basis throughout the periods covered
thereby, except in the case of unaudited, interim historical financial statements subject to normal year-end adjustments and
which do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules
included or incorporated by reference in the Registration Statement present fairly the information required to be stated
therein; and the other historical financial information of the Company included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the
Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby; <FONT STYLE="color: windowtext">and
any pro forma financial information and related notes thereto included or incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and the Prospectus </FONT>(i) have been prepared in accordance with Article 11 of
Regulation S-X with respect to <U>pro forma </U>financial statements and (ii) have been properly presented on the bases
described therein; the assumptions underlying such <U>pro forma</U> financial information included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus are a reasonable basis for presenting the effects attributable
to the transactions and circumstances referred to therein and the <FONT STYLE="color: windowtext">adjustments used therein
are appropriate to give effect to the transactions or circumstances referred to therein. All &#8220;non-GAAP financial
measures&#8221; (as such term is defined in the rules and regulations of the Commission) included or incorporated by
reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply with Regulation G under the
Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable, in all material respects. </FONT>To
the Company&#8217;s knowledge, the financial statements of WageWorks, Inc. (including the related notes thereto) and its
consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package
and the Prospectus present fairly in all material respects the consolidated financial position of WageWorks, Inc. and its
consolidated subsidiaries as of the dates indicated and the consolidated results of their operations for the periods
specified; and, except as stated therein, to the Company&#8217;s knowledge, such financial statements have been prepared in
conformity with generally accepted accounting principles in the United States applied on a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Material Adverse Change. </I>Since the date of the most recent financial statements of the Company included or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change
in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as
outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement,
the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries,
or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital
stock, or any material adverse change, or any development that could reasonably be expected to result in a material adverse change
in, or affecting the business, properties, management, financial position, stockholders&#8217; equity, results of operations or
prospects of the Company and its subsidiaries taken as a whole;(ii) neither the Company nor any of its subsidiaries has entered
into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries
taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries
taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business
that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator
or governmental or regulatory authority, except in each case of (i), (ii) and (iii) above, as otherwise disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Organization and Good Standing. </I>The Company and each of its &#8220;significant subsidiaries&#8221; (as such term
is defined in Rule 1-02 of Regulation S-X) have been duly organized and are validly existing and in good standing under the laws
of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction
in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification,
and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually
or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#8217;
equity or results of operations of the Company and its subsidiaries taken as a whole or on the performance by the Company of its
obligations under this Agreement (a &#8220;<B>Material Adverse Effect</B>&#8221;). The Company does not own or control, directly
or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Capitalization. </I>The
Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the
Prospectus under the heading &#8220;Capitalization&#8221; and &#8220;Description of Capital Stock&#8221;; all the outstanding
shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable
and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in
or expressly contemplated by the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including,
without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for,
any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment,
agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such
subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the
Company conforms in all material respects to the description thereof included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or
other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized
and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors&#8217; qualifying
shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security
interest, restriction on voting or transfer or any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Stock Options. </I>With respect to the outstanding stock options (the &#8220;<B>Stock Options</B>&#8221;) granted pursuant
to the stock-based compensation plans of the Company and its subsidiaries (the &#8220;<B>Company Stock Plans</B>&#8221;), (i) other
than Stock Options granted under the Company&#8217;s 2003 Stock Plan and 2005 Stock Plan, each Stock Option intended to qualify
as an &#8220;incentive stock option&#8221; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#8220;<B>Code</B>&#8221;)
so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option
was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors
of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary
number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each
party thereto, and (iii) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and
all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Select Market (the &#8220;<B>Nasdaq</B>&#8221;).
Each Company Stock Plan is accurately described in all material respects in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company
of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement
of material information regarding the Company or its subsidiaries or their results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Due Authorization. </I>The Company has full right, power and authority to execute and deliver this Agreement and to perform
its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by
it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>The Securities</I>. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company,
and when issued and delivered and paid for as described herein, will be duly and validly issued and will be fully paid and non-assessable
and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Violation or Default. </I>Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws
or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would
constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party
or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of
its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court
or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries, except,
in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate,
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of
the Shares by the Company pursuant to this Agreement and the consummation of the transactions contemplated by this Agreement do
not and will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default
under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or
any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which
any of the property or assets of the Company, or any of its subsidiaries is subject, (ii) result in any violation of the provisions
of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the
violation by the Company or any of its subsidiaries of any law or statute or any judgment, order, rule or regulation of any court
or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict,
breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Consents Required. </I>No consent, filing, approval, authorization, order, license, registration or qualification
of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance
by the Company of this Agreement, the issuance and sale of the Shares by the Company pursuant to this Agreement and the consummation
of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such
consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory
Authority, Inc. (&#8220;<B>FINRA</B>&#8221;) or the Nasdaq and under applicable state securities laws in connection with the purchase
and distribution of the Shares by the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Legal Proceedings. </I>Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any
of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject
that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect; to the knowledge of the
Company, no such investigations, actions, suits or proceedings are threatened, or contemplated by any governmental or regulatory
authority or threatened by others; and (i) there are no current or pending legal, governmental or regulatory actions, suits or
proceedings that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and
(ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed
as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus
that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Independent Accountants</I>. (i) PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company
and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within
the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States)
and as required by the Securities Act and (ii) to the knowledge of the Company, BDO USA, LLP, who has certified certain financial
statements of WageWorks, Inc. and its subsidiaries was previously an independent registered public accounting firm with respect
to WageWorks, Inc. and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company
Accounting Oversight Board (United States) and as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <I>Title to Real and Personal Property</I>. The Company and its subsidiaries have good and marketable title in fee simple
(in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal
property and assets that are material to the respective businesses of the Company and its subsidiaries, taken as a whole, in each
case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) could not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Title to Intellectual Property</I>. Except as could not reasonably be expected to have a Material Adverse Effect or as
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries own
or possess adequate rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations,
service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) necessary for the conduct of their respective businesses as currently
conducted and as proposed to be conducted, and the conduct of their respective businesses will not conflict in any material respect
with any such rights of others. The Company and its subsidiaries have not received any written notice of any claim of infringement,
misappropriation or conflict with any such rights of others in connection with its patents, patent rights, licenses, inventions,
trademarks, service marks, trade names, copyrights and know-how, which could reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Cybersecurity; Data Protection</I>. The Company&#8217;s and its subsidiaries&#8217; information technology assets and
equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<B>IT
Systems</B>&#8221;) are reasonably believed by the Company to be adequate in all material respects for, and operate and perform
in all material respects as required in connection with, the operation of the business of the Company and its subsidiaries as currently
conducted and, to the Company&#8217;s knowledge, are free and clear of all material bugs, errors, defects, Trojan horses, time
bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable
controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity,
continuous operation, redundancy and security of all IT Systems and data reasonably consistent with industry standards and practices,
or as required by applicable regulatory standards (and including all personal, personally identifiable, sensitive, confidential
or regulated data) (&#8220;<B>IT Data</B>&#8221;) and, to the knowledge of the Company there have been no material breaches, violations,
outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability.
The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules
and regulations of any court or arbitrator or governmental or regulatory authority and internal policies and contractual obligations
relating to the privacy and security of IT Systems and IT Data and to the protection of such IT Systems and IT Data from unauthorized
use, access, misappropriation or modification, except for such failures as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Data
Privacy and Security Laws</I>. Except as could not reasonably be expected to have a Material Adverse Effect or as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries are, and
since the Company&#8217;s inception have been, in compliance with all applicable state and federal data privacy and security
laws and regulations, including without limitation the Health Insurance Portability and Accountability Act of 1996
(&#8220;<B>HIPAA</B>&#8221;) as amended by the Health Information Technology for Economic and Clinical Health Act (the
 &#8220;<B>HITECH Act</B>&#8221;) (collectively, the &#8220;<B>Privacy Laws</B>&#8221;). To ensure compliance with the Privacy
Laws, the Company and its subsidiaries have in place, comply in all material respects with, and take appropriate steps
reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy
and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the
 &#8220;<B>Policies</B>&#8221;). &#8220;<B>Personal Data</B>&#8221; means (i) a natural person&#8217;s name, street address,
telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license
number, passport number, credit card number, bank information, or customer or account number; (ii) any information which
would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii)
Protected Health Information as defined by HIPAA; and (iv) any other piece of information that allows the identification of
such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&#8217;s health or sexual orientation. Except as could not reasonably be expected to have a Material Adverse Effect or
as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its
subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or
requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been
inaccurate or in violation of any applicable laws and regulatory rules or requirements. Except as could not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect, neither the Company nor any of its
subsidiaries: (i) has received notice of any actual or potential liability under or relating to, or actual or potential
violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to
result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes
any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Complaints</I>. There is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently
pending against the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&#8217;s
use of the products or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services
and any office contained therein (&#8220;<B>HHS</B>&#8221;), or any similar authority in any jurisdiction other than the Unites
States or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by the
Company or its subsidiaries, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened, except
<FONT STYLE="color: windowtext">as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of
its significant subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company
or any of its significant subsidiaries on the other, that is required by the Securities Act to be described in the Registration
Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Investment Company Act</I>. The Company is not, and after giving effect to the issuance and sale of the Shares by the
Company pursuant to this Agreement and the application of the proceeds thereof received by the Company as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#8220;investment company&#8221;
or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of
1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;<B>Investment Company Act</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Taxes. </I>The
Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be
paid or filed through the date hereof except for taxes being contested in good faith and for which reserves in accordance
with GAAP have been taken; and except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted
against the Company or any of its subsidiaries or any of their respective properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Licenses and Permits. </I>The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess
or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice
of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any
such license, certificate, permit or authorization will not be renewed in the ordinary course, except in each case as would not
reasonably be expected to have a Material Adverse Effect. To the Company&#8217;s knowledge, no party granting any such licenses,
certificates, permits and other authorizations has taken any action to limit, suspend or revoke the same in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Labor Disputes. </I>No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists
or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor
disturbance by, or dispute with, the employees of any of its or its subsidiaries&#8217; principal suppliers, contractors or customers,
except as would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Compliance with and Liability under Environmental Laws.</I> (i) The Company and its subsidiaries (a) are, and since the
Company&#8217;s inception were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations,
requirements, decisions, judgments, decrees, orders and the common law relating to pollution or the protection of the environment,
natural resources or human health or safety, including those relating to the generation, storage, treatment, use, handling, transportation,
Release or threat of Release of Hazardous Materials (collectively, &#8220;<B>Environmental Laws</B>&#8221;), (b) have received
and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable
Environmental Laws to conduct their respective businesses, (c) have not received notice of any actual or potential liability under
or relating to, or actual or potential violation of, any Environmental Laws, including for the investigation or remediation of
any Release or threat of Release of Hazardous Materials, and have no knowledge of any event or condition that would reasonably
be expected to result in any such notice, (d) are not conducting or paying for, in whole or in part, any investigation, remediation
or other corrective action pursuant to any Environmental Law at any location, and (e) are not a party to any order, decree or agreement
that imposes any obligation or liability under any Environmental Law, and (ii) there are no costs or liabilities associated with
Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any
such matter, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)
except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) there are no proceedings
that are pending or, to the knowledge of the Company, contemplated against the Company or any of its subsidiaries under any Environmental
Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary
sanctions of $100,000 or more will be imposed, (b) the Company and its subsidiaries are not aware of any facts or issues regarding
the Company&#8217;s or its subsidiaries&#8217; compliance with Environmental Laws, or liabilities or other obligations under Environmental
Laws, including the Release or threat of Release of Hazardous Materials, that could reasonably be expected to have a Material Adverse
Effect, and (c) none of the Company and its subsidiaries anticipates material capital expenditures relating to any Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Hazardous Materials</I>. There has been no storage, generation, transportation, use, handling, treatment, Release or
threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge
of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the Company or any
of its subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously
owned, operated or leased by the Company or any of its subsidiaries or at, on, under or from any other property or facility, in
violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any
liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. &#8220;<B>Hazardous Materials</B>&#8221; means any material, chemical,
substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum
(including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials,
naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental
Law. &#8220;<B>Release</B>&#8221; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting,
escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into
from or through any building or structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Compliance
with ERISA.</I> (i) Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income
Security Act of 1974, as amended (&#8220;<B>ERISA</B>&#8221;), for which the Company or any member of its &#8220;Controlled
Group&#8221; (defined as any organization which is a member of a controlled group of corporations within the meaning of
Section&nbsp;414 of the Code) would have any liability and which is established or maintained by the Company for the benefit
of its employees (each, a &#8220;<B>Plan</B>&#8221;) has been maintained in compliance with its terms and the requirements of
any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code, except for
noncompliance that could not reasonably be expected to result in material liability to the Company or its subsidiaries; (ii)
no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred
with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption that could
reasonably be expected to result in a material liability to the Company or its subsidiaries; (iii) for each Plan that is
subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, the minimum funding standard of
Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, as applicable, has been satisfied (without taking into account any
waiver thereof or extension of any amortization period) and is reasonably expected to be satisfied in the future (without
taking into account any waiver thereof or extension of any amortization period); (iv) to the extent applicable to a Plan, the
fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined
based on those assumptions used to fund such Plan); (v) no &#8220;reportable event&#8221; (within the meaning of
Section&nbsp;4043(c) of ERISA) has occurred or is reasonably expected to occur that either has resulted, or could reasonably
be expected to result, in material liability to the Company or its subsidiaries; (vi) neither the Company nor any member of
the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than
contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan
(including a &#8220;multiemployer plan&#8221;, within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (vii) there is no
pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty
Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably
be expected to result in material liability to the Company or its subsidiaries. None of the following events has occurred or
is reasonably likely to occur: (x) a material increase in the aggregate amount of contributions required to be made to all
Plans by the Company or its subsidiaries in the current fiscal year of the Company and its subsidiaries compared to the
amount of such contributions made in the Company and its subsidiaries&#8217; most recently completed fiscal year; or (y) a
material increase in the Company and its subsidiaries&#8217; &#8220;accumulated post-retirement benefit obligations&#8221;
(within the meaning of Statement of Financial Accounting Standards 106) compared to the amount of such obligations in the
Company and its subsidiaries&#8217; most recently completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Disclosure Controls</I>. Except as disclosed in the Registration Statement, the Prospectus and the Pricing Disclosure
Package, the Company and its subsidiaries maintain an effective system of &#8220;disclosure controls and procedures&#8221; (as
defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed
to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management
as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations
of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Accounting Controls. </I>The Company and its subsidiaries maintain effective systems of &#8220;internal control over
financial reporting&#8221; (as defined in Rule 13a-15(f) of the Exchange Act) that are designed to comply with the requirements
of Rule 13a-15(a) of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive
and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but
not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in
accordance with management&#8217;s general or specific authorization; and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences, except as disclosed
in the Registration Statement, the Prospectus and the Pricing Disclosure Package. Based on the Company&#8217;s most recent evaluation
of its internal controls over financial reporting pursuant to Rule 13a-15(c) of the Exchange Act, there are no material weaknesses
in the Company&#8217;s internal controls, except as disclosed in the Registration Statement, the Prospectus and the Pricing Disclosure
Package. The Company&#8217;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)
all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which
have adversely affected or are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize
and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who
have a significant role in the Company&#8217;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>eXtensible Business Reporting Language</I>. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Insurance. </I>The
Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses,
including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the
Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and
neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that
capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)
any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or
to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business except <FONT STYLE="color: windowtext">as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Unlawful Payments. </I>Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the
Company or any of its subsidiaries nor, to the knowledge of the Company, any agent or affiliate of the Company or any of its subsidiaries
(in their capacities as such) has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful expense
relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or
indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee, including of any
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for
or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated
or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended (&#8220;<B>FCPA</B>&#8221;), or any
applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery
or anti-corruption laws; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other
unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper
payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce
policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been
conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions
where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the &#8220;<B>Anti-Money
Laundering Laws</B>&#8221;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority
or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>No
Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or employees, nor, to
the knowledge of the Company, any agent or affiliate of the Company or any of its subsidiaries (in their capacities as such)
is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, (including, without
limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and
including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked
person&#8221;), the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, or other relevant
sanctions authority (collectively, &#8220;<B>Sanctions</B>&#8221;), nor is the Company or any of its subsidiaries located,
organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, Crimea, Cuba, Iran, North Korea and Syria (each, a &#8220;<B>Sanctioned Country</B>&#8221;); and the Company will
not, directly or indirectly, use the proceeds of the sale of the Shares hereunder, or lend, contribute or otherwise make
available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any
activities of or business with any person that, at the time of such funding or facilitation, is the subject or the target of
Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner
that will result in a violation by any person (including any person participating in the transaction, whether as underwriter,
advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly
engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any person that at
the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly, under
any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any
other distribution on such subsidiary&#8217;s capital stock, from repaying to the Company any loans or advances to such subsidiary
from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Broker&#8217;s Fees. </I>Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its
subsidiaries or the Underwriter for a brokerage commission, finder&#8217;s fee or like payment in connection with the issuance
and sale of the Shares by the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Registration Rights</I>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the
Prospectus and which have been duly waived, no person has the right to require the Company or any of its subsidiaries to register
any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the
issuance and sale of the Shares by the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Stabilization. </I>The Company has not taken, directly or indirectly, without giving effect to the activities of the
Underwriter, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation
of the price of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(qq)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Forward-Looking Statements. </I>No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in the Registration Statement, the Pricing
Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in
good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(rr)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Statistical and Market Data. </I>Nothing has come to the attention of the Company that has caused the Company to believe
that the statistical and market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ss)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#8217;s directors
or executive officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including Section&nbsp;402
related to loans and Sections&nbsp;302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(tt)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the
meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#8220;ineligible
issuer,&#8221; and is a well-known seasoned issuer, in each case as defined in Rule 405 under the Securities Act. The Company has
paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the
time period required by such rule (without giving effect to the proviso therein) and in any event prior to the <FONT STYLE="color: windowtext">Closing
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(uu)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="color: windowtext"><I>Accuracy of Disclosure</I>. The statements set forth in the Registration Statement,
under the caption &#8220;Description of Securities&#8211;Common Stock,&#8221; as supplemented and updated by the discussion set
forth in the Prospectus under the heading &#8220;Description of Common Stock,&#8221; and the statements set forth in the Prospectus
under the heading &#8220;Certain Material U.S. Federal Income Tax and Estate Tax Consequences to Non-U.S. Holders,&#8221; insofar
as they purport to summarize the provisions of the laws and documents referred to therein, are accurate in all material respects</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares by the Company nor the application of the proceeds
thereof by the Company as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate
Regulation T, U or X of the Board of Governors of the Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Further Agreements of the Company</U>. The Company covenants and agrees with the Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Required Filings. </I>The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430B under the Securities Act; will file any Issuer Free Writing Prospectus to the extent required by Rule
433 under the Securities Act; will file promptly all reports and any definitive proxy or information statements required to be
filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the
date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the
Shares; and will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered)
to the Underwriter in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this
Agreement in such quantities as the Underwriter may reasonably request<FONT STYLE="color: windowtext">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Copies. </I>The Company will deliver, without charge, (i) to the Underwriter, if requested, one signed copy
of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents
filed therewith and documents incorporated by reference therein; and (ii) to the Underwriter (A) a conformed copy of the Registration
Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined
below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference
therein and each Issuer Free Writing Prospectus) as the Underwriter may reasonably request. As used herein, the term &#8220;<B>Prospectus
Delivery Period</B>&#8221; means such period of time after the first date of the public offering of the Shares pursuant to this
Agreement as in the opinion of counsel for the Underwriter a prospectus relating to the Shares is required by law to be delivered
(or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by the Underwriter
or dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Amendments or Supplements, Issuer Free Writing Prospectuses. </I>Before preparing, using, authorizing, approving, referring
to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or
the Prospectus, the Company will furnish to the Underwriter and counsel for the Underwriter a copy of the proposed Issuer Free
Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any such
Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Underwriter reasonably objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Notice
to the Underwriter. </I>The Company will advise the Underwriter promptly, and confirm such advice in writing (which may be by
electronic mail), (i) when any amendment to the Registration Statement has been filed or becomes effective; (ii) when any
supplement to the Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or
distributed; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or
supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any
other request by the Commission for any additional information; (iv) of the issuance by the Commission of any order
suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus,
any of the Pricing Disclosure Package or the Prospectus or the initiation or threatening of any proceeding, if the Company
gains knowledge of such proceeding, for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (v) of the
occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing
Disclosure Package or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package or any
such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; (vi) of the receipt by the Company of any
notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto
pursuant to Rule 401(g)(2) under the Securities Act; and (vii) of the receipt by the Company of any notice with respect to
any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of
any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such
order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary
Prospectus, the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Shares and, if any
such order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Ongoing Compliance.</I> (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition
shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary
to amend or supplement the Prospectus to comply with law, the Company will immediately notify the Underwriter thereof and forthwith
prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriter and to such dealers as the
Underwriter may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and
incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or
any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances
existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)
if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which
the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the
Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing
Disclosure Package to comply with law, the Company will immediately notify the Underwriter thereof and forthwith prepare and, subject
to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriter and to such dealers as
the Underwriter may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with
the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package
as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered
to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Blue
Sky Compliance. </I>The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such
jurisdictions as the Underwriter shall reasonably request and will continue such qualifications in effect so long as required
for distribution of the Shares; <U>provided</U> that the Company shall not be required to (i) qualify as a foreign
corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to
so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation
in any such jurisdiction if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Earning Statement. </I>The Company will make generally available to its security holders and the Underwriter as soon
as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of
the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the
Company occurring after the &#8220;effective date&#8221; (as defined in Rule 158) of the Registration Statement; <U>provided</U>
the Company will be deemed to have furnished such earning statement to its security holders and the Underwriter to the extent it
is filed on the Commission&#8217;s Electronic Data Gathering, Analysis, and Retrieval system (&#8220;<B>EDGAR</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Clear Market. </I>For a period of 45 days after the date of the Prospectus, the Company will not (i) offer, pledge, announce
the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or file with
the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible
into or exercisable or exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition
or filing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to
be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Underwriter,
other than (A) the Shares to be sold hereunder, (B) any shares of Common Stock of the Company issued upon the exercise, vesting
or settlement of options, restricted stock units, stock appreciation rights or other awards granted under or covered by the Company
Stock Plans, (C) any shares of Common Stock of the Company issued upon the exercise of warrants outstanding on the date of the
Prospectus, as described in the Registration Statement, Pricing Disclosure Package and the Prospectus, (D) sales of securities
of the Company pursuant to the Company&#8217;s employee stock purchase plan and grants of equity awards under the Company Stock
Plans, in each case as described in the Registration Statement, Pricing Disclosure Package and Prospectus, (E) the filing of a
registration statement on Form S-8 as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
(F) the issuance of shares of Stock or other securities (including securities convertible into shares of Stock) in connection with
the acquisition by the Company or any of its subsidiaries of the securities, businesses, properties or other assets of another
person or entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition, or (G)
the issuance of shares of Stock or other securities (including securities convertible into shares of Stock) pursuant to equipment
leasing arrangements or debt financing; <U>provided</U> that, in the case of clauses (F) and (G), it being understood that any
recipient shall enter into a lock-up letter with the Underwriter in the form contemplated by Exhibit&nbsp;A; <U>provided</U> that
in the case of clause (G) no filings are required to be made under Section&nbsp;16(a) of the Exchange Act in connection with such
issuance; <U>provided</U> further that, in the case of clauses (F) and (G), taken together, no more than 5.0% of the total outstanding
shares of Stock as of the Closing Date are transferred, in the aggregate, during the 45-day restricted period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Stabilization. </I>The Company will not take, directly or indirectly, without giving effect to the activities taken
by the Underwriter, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation
of the price of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Use of Proceeds</I>. The Company will apply the net proceeds from the sale of the Shares pursuant to this Agreement as
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#8220;Use of Proceeds.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Exchange Listing</I>. The Company will use commercially reasonable efforts to list the Stock on the Nasdaq. The Company
will use commercially reasonable efforts to maintain such listing of the Stock on the Nasdaq for so long as the Securities are
outstanding and the Company&#8217;s Common Stock is listed on the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Reports. </I>For a period of two years from the date of this Agreement, the Company will furnish to the Underwriter,
promptly after the date they are available, copies of all reports or other communications (financial or other) furnished to holders
of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities
exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial
statements to the Underwriter to the extent they are filed on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each
Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Filings. </I>The Company will file with the Commission such reports as may be required by Rule 463 under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Certain Agreements of the Underwriter</U>. The Underwriter hereby represents and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize
use of, refer to or participate in the planning for use of, any &#8220;free writing prospectus&#8221;, as defined in Rule 405 under
the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated
by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus
that contains no &#8220;issuer information&#8221; (as defined in Rule 433(h)(2) under the Securities Act) that was not included
(including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus,
(ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above
(including any electronic road show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company
in advance in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains
the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission;
<U>provided</U> that the Underwriter may use a term sheet substantially in the form of Annex B hereto without the consent of the
Company; <U>provided</U><I>, </I><U>further</U>, that the Underwriter using such term sheet shall notify the Company, and provide
a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering contemplated
by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery
Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Conditions of Underwriter&#8217;s Obligations</U>. The obligation of the Underwriter to purchase the Underwritten
Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject
to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Registration Compliance; No Stop Order. </I>No order suspending the effectiveness of the Registration Statement shall
be in effect, and no proceeding for such purpose pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities
Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have
been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent
required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission
for additional information shall have been complied with to the reasonable satisfaction of the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Representations and Warranties. </I>The respective representations and warranties of the Company contained herein shall
be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and
the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and
correct on and as of the Closing Date or the Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Downgrade. </I>Subsequent to the earlier of (A) the Applicable Time and (B) the execution and delivery of this Agreement, if there
are any debt securities or preferred stock of, or guaranteed by, the Company or any of its subsidiaries that are rated by a &#8220;nationally
recognized statistical rating organization,&#8221; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act, (i) no
downgrading shall have occurred in the rating accorded any such debt securities or preferred stock and (ii) no such organization
shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its rating
of any such debt securities or preferred stock (other than an announcement with positive implications of a possible upgrading).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Material Adverse Change. </I>No event or condition of a type described in Section&nbsp;3(g) hereof shall have occurred or shall
exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto)
and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Underwriter
makes it impracticable or inadvisable to proceed with the issuance, offering, sale or delivery of the Shares on the Closing Date
or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing
Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Officers&#8217;
Certificate. </I>The Underwriter shall have received on and as of the Closing Date or the Additional Closing Date, as the case
may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive
officer of the Company who is reasonably satisfactory to the Underwriter (i) confirming that such officers have carefully reviewed
the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations
of the Company set forth in Sections&nbsp;3(b) and 3(d) hereof are true and correct, (ii) confirming that the other representations
and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and
satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional
Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a), (c) and (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Chief Financial Officer&#8217;s Certificate</I>. The Underwriter shall have received a certificate, dated such Closing
Date, of the Chief Financial Officer of the Company, in form and substance satisfactory to the Underwriter, substantially to the
effect set forth in Exhibit&nbsp;B attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Comfort
Letters. </I>On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, each
of PricewaterhouseCoopers LLP and BDO USA, LLP shall have furnished to the Underwriter, at the request of the Company,
letters, dated the respective dates of delivery thereof and addressed to the Underwriter, in form and substance reasonably
satisfactory to the Underwriter, containing statements and information of the type customarily included in accountants&#8217;
 &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information
included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; <U>provided</U>,
that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a
 &#8220;cut-off&#8221; date no more than three business days prior to such Closing Date or such Additional Closing Date, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion and Negative Assurance Letter of Counsel for the Company. </I>Willkie Farr &amp; Gallagher LLP, counsel for the
Company, shall have furnished to the Underwriter, at the request of the Company, their written opinion and negative assurance letter,
dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriter, in form and substance
reasonably satisfactory to the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion and Negative Assurance Letter of Counsel for the Underwriter. </I>The Underwriter shall have received on and
as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and negative assurance letter of Latham &amp;
Watkins LLP, counsel for the Underwriter, with respect to such matters as the Underwriter may reasonably request, and such counsel
shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Legal Impediment to Issuance and/or Sale. </I>No action shall have been taken and no statute, rule, regulation or
order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would,
as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company
pursuant to this Agreement; and no injunction or order of any federal, state or foreign court shall have been issued that would,
as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company
pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>[Reserved].</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Exchange Listing. </I>The Shares to be delivered on the Closing Date or Additional Closing Date, as the case may be,
shall have been approved for listing on the Nasdaq, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Lock-up Agreements</I>. The &#8220;lock-up&#8221; agreements, each substantially in the form of Exhibit&nbsp;A hereto,
between you and each of the individuals and entities set forth on Annex C, relating to sales and certain other dispositions of
shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on
the Closing Date or Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Additional Documents. </I>On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company
shall have furnished to the Underwriter such further certificates and documents as the Underwriter may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and
evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if
they are in form and substance reasonably satisfactory to counsel for the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Indemnification and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <I>Indemnification of the Underwriter by the Company. </I>The Company agrees to indemnify and hold harmless the Underwriter,
its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities
(including, without limitation, reasonable and documented legal fees and other reasonable and documented expenses incurred in connection
with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based
upon, (i) any untrue statement or alleged untrue statement of a material fact included or incorporated by reference in the Registration
Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary
in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material
fact included or incorporated by reference in the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing
Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Securities Act,
any road show as defined in Rule 433(h) under the Securities Act (a &#8220;road show&#8221;) or any Pricing Disclosure Package
(including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to
state therein a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities
arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon
and in conformity with any information relating to the Underwriter furnished to the Company in writing by the Underwriter expressly
for use therein, it being understood and agreed that the only such information furnished by the Underwriter consists of the information
described as such in subsection&nbsp;(b) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Indemnification of the Company. </I>The Underwriter agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above,
but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement
or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to the
Underwriter furnished to the Company in writing by the Underwriter expressly for use in the Registration Statement, the Prospectus
(or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any road show or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information
furnished by the Underwriter consists of the following information in the Prospectus furnished on behalf of the Underwriter: the
tenth through thirteenth paragraphs in the Prospectus under the heading &#8220;Underwriting.&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Notice
and Procedures. </I>If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding
paragraphs of this Section&nbsp;7, such person (the &#8220;<B>Indemnified Person</B>&#8221;) shall promptly notify the person
against whom such indemnification may be sought (the &#8220;<B>Indemnifying Person</B>&#8221;) in writing; <U>provided </U>that
the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding
paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of
substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the
Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under
the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified
Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably
satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the
Indemnifying Person) to represent the Indemnified Person in such proceeding and shall pay the fees and expenses of such
counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to
retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless
(i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying
Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the
Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from
or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any
impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interest between them. It is understood and agreed
that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be
liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified
Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for the
Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in
writing by the Underwriter and any such separate firm for the Company, its directors, its officers who signed the
Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying
Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified
Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified
Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any
settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days
after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the
Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall,
without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in
respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by
such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and
substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of
such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or
on behalf of any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Contribution. </I>If
the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such
paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such
Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to
reflect the relative benefits received by the Company, on the one hand, and the Underwriter on the other, from the offering
of the Shares pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law,
in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the
relative fault of the Company, on the one hand, and the Underwriter on the other, in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriter on the other, in
connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective
proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares pursuant to
this Agreement and the total underwriting discounts and commissions received by the Underwriter in connection therewith, in
each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The
relative fault of the Company, on the one hand, and the Underwriter on the other, shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or by the Underwriter and the parties&#8217; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Limitation on Liability. </I>The Company and the Underwriter agree that it would not be just and equitable if contribution
pursuant to paragraph (d) above were determined by <U>pro rata</U> allocation or by any other method of allocation that does not
take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person
as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such
action or claim. Notwithstanding the provisions of paragraphs (d) and (e) of this Section 7, in no event shall the Underwriter
be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received
by the Underwriter with respect to the offering of the Shares pursuant to this Agreement exceeds the amount of any damages that
the Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Non-Exclusive Remedies. </I>The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any
rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Effectiveness of Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by
the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Underwriter, by notice to
the Company, if after the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option
Shares, prior to the Additional Closing Date: (i) trading generally shall have been suspended or materially limited on or by any
of the New York Stock Exchange, or the Nasdaq; (ii) trading of any securities issued or guaranteed by the Company shall have been
suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall
have been declared by federal or New York State authorities; (iv) there shall have occurred any major disruption of settlements
of securities, payment or clearance services in the United States or any other country where such securities are listed; or (v)
there shall have occurred any outbreak or escalation of hostilities or declaration by the United States of a national emergency
or war or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment
of the Underwriter, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery
of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated
by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Defaulting
Underwriter</U>. If the Underwriter shall default in its obligation to purchase the Shares which it has agreed to purchase
hereunder, then this Agreement shall thereupon terminate, without liability on the part of the Company except for the
expenses to be borne by the Company and the Underwriter as provided in Section 11 hereof, and the indemnity and contribution
agreements provided in Section 7 hereof; but nothing herein shall relieve the defaulting Underwriter from liability for its
default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company
will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without
limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable
in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration
Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including
all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of the Company&#8217;s
counsel and independent accountants; (iv) the fees and expenses incurred in connection with the registration or qualification of
the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Underwriter may designate and the
preparation, printing and distribution of a Blue Sky Memorandum and any &#8220;Canadian wrapper&#8221; (including the related fees
and expenses of counsel for the Underwriter not to exceed an aggregate of $10,000); (v) the cost of preparing stock certificates;
(vi) the costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection
with any filing with, and clearance of the offering by, FINRA (including the fees and expenses of counsel for the Underwriter not
to exceed an aggregate of $25,000); (viii) all expenses and application fees related to the listing of the Stock on the Nasdaq;
and (ix) all expenses incurred by the Company in connection with any &#8220;road show&#8221; presentation to potential investors.
Except as provided for by this Agreement, the Underwriter will pay all of its own expenses, including the fees of its counsel and
travel and lodging expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If (i) this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares
for delivery to the Underwriter or (iii) the Underwriter declines to purchase the Shares for any reason permitted under this Agreement,
the Company agrees to reimburse the Underwriter for all out-of-pocket costs and expenses (including the fees and expenses of its
counsel) reasonably incurred by the Underwriter in connection with this Agreement and the offering contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section&nbsp;7
hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy
or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from the Underwriter shall
be deemed to be a successor merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements of
the Company and the Underwriter contained in this Agreement or made by or on behalf of the Company or the Underwriter pursuant
to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall
remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the
Company or the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Certain
Defined Terms</U>. For purposes of this Agreement, (a) except where otherwise expressly provided, the term
 &#8220;affiliate&#8221; has the meaning set forth in Rule 405 under the Securities Act; (b) the term &#8220;business
day&#8221; means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the
term &#8220;subsidiary&#8221; has the meaning set forth in Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Notices. </I>All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriter shall be directed
to BofA Securities, Inc. at One Bryant Park, New York, New York 10036, attention of Syndicate Department (facsimile: (646) 855-3073),
with a copy to ECM Legal (facsimile: (212) 230-8730). Notices to the Company shall be given to it at HealthEquity, Inc., 15 West
Scenic Pointe Drive, Draper, Utah 84020, (fax: (801) 727-1005), Attention: Delano Ladd, Executive Vice President, General Counsel
and Corporate Secretary, with a copy to (which shall not constitute notice): Willkie Farr &amp; Gallagher LLP, 787 Seventh Avenue,
New York, N.Y. 10019 (fax: (212) 728-8111), Attention: Matthew Haddad, Esq. and Jeffrey S. Hochman, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Governing Law. </I>This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall
be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed
in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: windowtext"><I>USA Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title
III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriter is required to obtain, verify and record information
that identifies the Underwriter&#8217;s clients, including the Company, which information may include the name and address of the
Underwriter&#8217;s clients, as well as other information that will allow the Underwriter to properly identify its clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Recognition of the U.S. Special Resolution Regimes</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that the Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from the Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be
effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that the Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to
a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter
are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution
Regime if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&#8220;<B><I>BHC Act Affiliate</I></B>&#8221;
has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &sect;
1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&#8220;<B><I>Covered Entity</I></B>&#8221;
means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i) a &#8220;covered entity&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii) a &#8220;covered bank&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(iii) a &#8220;covered FSI&#8221;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&#8220;<B><I>Default Right</I></B>&#8221;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&#8220;<B><I>U.S. Special Resolution
Regime</I></B>&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Waiver of Jury Trial</I>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any
and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Counterparts. </I>This Agreement may be executed in any number of counterparts (which may include counterparts delivered
by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together
constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Amendments or Waivers. </I>No amendment or waiver of any provision of this Agreement, nor any consent or approval to
any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Headings. </I>The headings herein are included for convenience of reference only and are not intended to be part of,
or to affect the meaning or interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Integration. </I>This Agreement supersedes all prior agreements and understandings (whether written or oral) between
the Company and the Underwriter, or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature pages follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your
understanding, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between the Underwriter and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">HEALTHEQUITY, INC.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/ Darcy Mott</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Darcy Mott</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive Vice President and Chief Financial
Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Accepted: As of the date first
    written above</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BOFA SECURITIES, INC.&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Omid Ahdieh</FONT></TD>
    <TD STYLE="width: 52%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Omid Ahdieh</P>
</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Managing Director</P>
</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page
to Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Schedule&nbsp;1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">BofA Securities, Inc.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>a.</B></TD><TD><B>Pricing Disclosure Package</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>b.</B></TD><TD><B>Pricing Information Provided Orally by Underwriter</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.6in; width: 26%">Purchase price per share to be paid by the Underwriter:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 72%">$79.50</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.6in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.6in">Public offering price per share:</TD>
    <TD>&nbsp;</TD>
    <TD>The public offering price per share is, as to each investor, the price paid by such investor.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.6in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.6in">Common Stock offered:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">5,000,000 shares of Common Stock, plus up to 750,000 shares of Common Stock issuable upon the exercise of the Underwriter&#8217;s option to purchase additional shares</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HealthEquity, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pricing Term Sheet</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex C</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Lock-up Parties</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Name&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edward Bloomberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Frank A. Corvino</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adrian T. Dillon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evelyn Dilsaver</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Angelique Hill</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adam Hostetter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jon Kessler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delano Ladd</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Debra McCowan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Darcy Mott</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tyson Murdock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen D. Neeleman, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William Robert Otten</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stuart Parker</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ian Sacks</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert W. Selander</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Larry Trittschuh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gayle Wellborn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit&nbsp;A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Lock-up Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February ___, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BOFA SECURITIES, INC.<BR>
One Bryant Park<BR>
New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>HealthEquity, Inc. &#8212; Public Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that you propose
to enter into an Underwriting Agreement (the &#8220;<B>Underwriting Agreement</B>&#8221;) between HealthEquity, Inc., a Delaware
corporation (the &#8220;<B>Company</B>&#8221;), and BofA Securities, Inc. ( &#8220;<B>BofAS</B>&#8221;), providing for the public
offering (the &#8220;<B>Public Offering</B>&#8221;) of common stock (the &#8220;<B>Common Stock</B>&#8221;), $0.0001 per share
par value, of the Company (the &#8220;<B>Securities</B>&#8221;). Capitalized terms used herein and not otherwise defined shall
have the meanings set forth in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of BofAS&#8217;
agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt
of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of BofAS, the
undersigned will not, during the period commencing on the date hereof and ending 45 days (the &#8220;<B>Lock-up
Period</B>&#8221;) after the date of the final prospectus relating to the Public Offering (the
 &#8220;<B>Prospectus</B>&#8221;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of,
directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially
owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and
securities which may be issued upon exercise of a stock option or warrant), or publicly disclose the intention to make any
offer, sale, pledge or disposition, (2) enter into any swap or other agreement that transfers, in whole or in part, any of
the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)
make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock (and for avoidance of doubt, the undersigned hereby waives
any and all notice requirements and rights with respect to the registration of any securities pursuant to any agreement,
instrument, understanding or otherwise, including any stockholders or registration rights agreement or similar agreement, to
which the undersigned is a party or under which the undersigned is entitled to any right or benefit), in each case other than
(A) the Securities to be sold by the undersigned pursuant to the Underwriting Agreement, if any, (B) transfers of shares of
Common Stock or such other securities as a bona fide gift or gifts, (C) transfers or dispositions of shares of Common Stock
or such other securities to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
undersigned in a transaction not involving a disposition for value, (D) transfers or dispositions of shares of Common Stock
or such other securities to any of the undersigned&#8217;s affiliates (as defined in Rule 405 promulgated under the
Securities Act of 1933, as amended) or to any investment fund or other entity controlled or managed by the undersigned, (E)
transfers or dispositions of shares of Common Stock or such other securities by will, other testamentary document or
intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned,
and (F) distributions of shares of Common Stock or such other securities to partners, members or stockholders of the
undersigned; <U>provided,</U> that in the case of any transfer, disposition or distribution pursuant to clause (B), (C), (D),
(E) or (F), each transferee, donee or distributee shall execute and deliver to BofAS a lock-up letter in the form of this
letter agreement; and <U>provided</U>, <U>further</U>, that in the case of any transfer, disposition or distribution pursuant
to clause (B), (C), (D) or (F), no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange
Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;), reporting a reduction in beneficial ownership or transfer or
disposition of any rights in Common Stock held by the undersigned or other public announcement shall be required or shall be
made voluntarily in connection with such transfer, disposition or distribution (other than a filing on a Form 5 made after
the expiration of the Lock-up Period). For purposes of this letter agreement, &#8220;immediate family&#8221; shall mean any
relationship by blood, marriage or adoption, not more remote than first cousin. Furthermore, notwithstanding the restrictions
imposed by this letter agreement, the undersigned may, without the prior written consent of BofAS, (i) exercise an option to
purchase shares of Common Stock granted under any stock incentive plan or stock purchase plan of the Company; <U>provided</U>,
that any shares of Common Stock received by the undersigned upon such exercise shall be subject to the restrictions on
transfer set forth in this letter agreement, and <U>provided</U>, <U>further</U>, that no filing under Section&nbsp;16(a) of
the Exchange Act or other public announcement shall be required or shall be voluntarily made within 30 days after the date of
the Prospectus, and after such 30th day, any filing under the Exchange Act shall clearly indicate in the footnotes thereto
that (a) the filing relates to the circumstances described in this clause (i), (b) no shares were sold by the reporting
person and (c) the shares received upon exercise of the option are subject to a lock-up agreement with BofAS; (ii) exercise
warrants to purchase shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock; <U>provided</U>,
that any shares of Common Stock received by the undersigned upon such exercise shall be subject to the restrictions set forth
in this letter agreement, (iii) transfer the undersigned&#8217;s Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock to the Company pursuant to any contractual arrangement in effect on the date of this letter
agreement that provides for the repurchase of the undersigned&#8217;s Common Stock or such other securities by the Company or
in connection with the termination of the undersigned&#8217;s employment with the Company, <U>provided</U> that no filing
under the Exchange Act or other public announcement shall be required or voluntarily made by the undersigned or any other
person in connection therewith, in each case during the Lock-up Period, (iv) transfer the undersigned&#8217;s Common Stock or
any security convertible into or exercisable or exchangeable for Common Stock to the Company in connection with a vesting
event of the Company&#8217;s securities or upon the exercise of warrants or options to purchase the Company&#8217;s
securities, on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis or to cover tax withholding obligations of the
undersigned in connection with such vesting or exercise, <U>provided</U> that the underlying shares shall continue to be
subject to the restrictions on transfer set forth in this letter agreement, (v) establish a trading plan pursuant to Rule
10b5-1 under the Exchange Act (&#8220;<B>Rule 10b5-1</B>&#8221;) for the transfer of Common Stock; <U>provided</U>, that such
plan does not provide for any transfers of Common Stock, and no filing with the Securities and Exchange Commission or other
public announcement shall be required or voluntarily made by the undersigned or any other person in connection therewith, in
each case during the Lock-up Period, (vi) transfer or dispose of Securities acquired on the open market following the Public
Offering; <U>provided </U>that no filing by any party under the Exchange Act reporting a reduction in beneficial ownership or
transfer or disposition of any rights in Common Stock held by the undersigned or other public announcement shall be required
or shall be made voluntarily in connection with such transfer or disposition (other than a filing on a Form 5 made after the
expiration of the Lock-up Period), and (vii) execute sales of Common Stock made pursuant to a trading plan pursuant to Rule
10b5-1 that has been entered into by the undersigned prior to the date of this letter agreement; <U>provided</U>, that to the
extent a public announcement or filing under the Exchange Act, if any, is required or voluntarily made by or on behalf of the
undersigned or the Company regarding any such sales, such announcement or filing shall include a statement to the effect that
the sale was made pursuant to a trading plan pursuant to Rule 10b5-1. Notwithstanding the foregoing, the undersigned shall be
permitted to make required filings on a Schedule&nbsp;13D, Schedule&nbsp;13F or Schedule&nbsp;13G under the Exchange Act,
provided that any such filings shall not be made in connection with a transfer, disposition or distribution of Common Stock
or any security convertible into or exercisable or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The restrictions contained herein shall
not apply to any transfers, sales, tenders or other dispositions of Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock pursuant to a bona fide third party tender offer, merger, amalgamation, consolidation or other
similar transaction made to or involving all holders of the Common Stock or such other securities pursuant to which one hundred
percent (100%) ownership of the Company is transferred to such third party (including, without limitation, the entering into any
lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose
of Common Stock or other such securities in connection with such transaction, or vote any Common Stock or other such securities
in favor of any such transaction); <U>provided</U>, that if such tender offer merger, amalgamation, consolidation or other similar
transaction is not completed, any Common Stock or any security convertible into or exercisable or exchangeable for Common Stock
subject to this letter agreement shall remain subject to the restrictions contained in this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In furtherance of the foregoing, the Company,
and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized
to decline to make any transfer of securities if such transfer would constitute a violation or breach of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby represents and warrants
that the undersigned has full power and authority to enter into this letter agreement. All authority herein conferred or agreed
to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives
of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby waives any and all
notice requirements and rights with respect to the registration of securities pursuant to any agreement, instrument, understanding
or otherwise, including any stockholders or registration rights agreement or similar agreement, to which the undersigned is a party
or under which the undersigned is entitled to any right or benefit, <U>provided</U>, however, that such waiver shall apply only
to the proposed Public Offering, and any other action taken by the Company in connection with the proposed Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned acknowledges and agrees
that BofAS have not provided any recommendation or investment advice nor have BofAS solicited any action from the undersigned with
respect to the offering of the securities and the undersigned has consulted their own legal, accounting, financial, regulatory
and tax advisors to the extent deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that, if (i)
BofAS, on the one hand, or the Company, on the other hand, inform the other in writing, prior to the execution of the Underwriting
Agreement, that it has determined not to proceed with the Public Offering, (ii) the Underwriting Agreement does not become effective
by May 17, 2021 (provided that the Company may by written notice to the undersigned extend such date for a period of up to two
additional months), (iii) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, or (iv) the registration statement
filed with the Securities and Exchange Commission in connection with the Public Offering is withdrawn, the undersigned shall be
released from all obligations under this letter agreement. The undersigned understands that the Company and BofAS are relying upon
this letter agreement in proceeding toward consummation of the Public Offering. Whether or not the Public Offering actually occurs
depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting
Agreement, the terms of which are subject to negotiation between the Company and BofAS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This letter agreement and any claim, controversy
or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with the laws of
the State of New York, without regard to the conflict of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Name
    of Security Holder</FONT> <FONT STYLE="font-size: 10pt">(Print exact name)</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">If not signing in an individual
    capacity:</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Name
    of Authorized Signatory </FONT><FONT STYLE="font-size: 10pt"><I>(Print)</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Title
    of Authorized Signatory </FONT><FONT STYLE="font-size: 10pt"><I>(Print)</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(indicate capacity of
    person signing if signing as custodian, trustee, or on behalf of an entity)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit&nbsp;B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Chief Financial Officer&#8217;s
Certificate</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20"><B>HEALTHEQUITY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20"><B><U>Chief Financial Officer&#8217;s
Certificate</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">February
16, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20; text-indent: 1in">I, Darcy
Mott, do hereby certify that I am Executive Vice President and Chief Financial Officer of HealthEquity, Inc., a Delaware corporation
(the &#8220;Company&#8221;), and, in my capacity as such, and not in any individual capacity, do hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #231F20">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231F20">I am providing this certificate in connection with the offering and
sale (the &#8220;Offering&#8221;) by the Company of </FONT>$401,500,000 of <FONT STYLE="color: #231F20">its Common Stock, (the
 &#8220;Shares&#8221;), pursuant to an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;), dated February 16. 2021,
by and between the Company and BofA Securities, Inc., as the underwriter (the &#8220;Underwriter&#8221;). </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; color: #231F20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">I am responsible for the financial and accounting matters of the Company and its subsidiaries,
including oversight of the financial and accounting functions and staff and I am familiar with the internal accounting records
and accounting practices, systems, policies and procedures of the Company and its subsidiaries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify; padding-right: 3.8pt">I have reviewed the Registration Statement and the Pricing Disclosure Package
and I have reviewed the circled items contained or incorporated by reference in the Registration Statement and the Pricing Disclosure
Package, attached as <U>Exhibit A</U> hereto (the &#8220;Identified Items&#8221;) as well as the financial statements and accounting
records of the Company used to prepare such Identified Items.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #231F20">4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 3.8pt">As of the date hereof, to the best of my knowledge, the Identified Items
(a) are true, accurate and complete in all material respects and (b) match or were accurately derived from the applicable internal
accounting and/or financial records of the Company in all material respects and/or were accurately derived from applicable internal
records or schedules prepared by the Company&#8217;s management in all material respects<FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20; text-indent: 0.5in">Capitalized
terms used but not defined herein shall have the meanings ascribed to such terms in the Underwriting Agreement. This Certificate
is being furnished to the Underwriter solely to assist it in conducting its investigation of the Company in connection with the
offering of the Shares and it is not to be used, circulated, quoted, or otherwise referred to for any other purpose. Each of Latham
 &amp; Watkins LLP, counsel for the Underwriter, and Willkie Farr &amp; Gallagher LLP, counsel to the Company, is entitled to rely
on this Certificate in connection with the opinions and letters that each firm is delivering pursuant to Sections 6(i) and 6(h),
respectively, of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">IN
WITNESS WHEREOF, the undersigned has executed and delivered this Chief Financial Officer&#8217;s Certificate on behalf of the Company
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-size: 10pt">Darcy Mott</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Executive Vice President and Chief Financial
    Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 301.5pt; text-indent: -67.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 301.5pt; text-indent: -67.5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>hqy-20210216.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaEWbOdzZR+GYkxtmB9bVmqbykovZuoYiliTVoW4aoM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:hqy="http://healthequity.com/20210216" elementFormDefault="qualified" targetNamespace="http://healthequity.com/20210216">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://healthequity.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20210216_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20210216_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>hqy-20210216_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>hqy-20210216_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://healthequity.com/role/Cover" xlink:href="hqy-20210216.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://healthequity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>tm216328d3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hqy-20210216.xsd" xlink:type="simple"/>
    <context id="From2021-02-16to2021-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001428336</identifier>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-02-16to2021-02-16">0001428336</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-02-16to2021-02-16">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-02-16to2021-02-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-02-16to2021-02-16">2021-02-16</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2021-02-16to2021-02-16">001-36568</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-02-16to2021-02-16">HEALTHEQUITY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-02-16to2021-02-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-02-16to2021-02-16">001-36568</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-02-16to2021-02-16">52-2383166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-02-16to2021-02-16">15 West Scenic Pointe Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-02-16to2021-02-16">Suite&#160;100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-02-16to2021-02-16">Draper</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-02-16to2021-02-16">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-02-16to2021-02-16">84020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-02-16to2021-02-16">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-02-16to2021-02-16">727-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-02-16to2021-02-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-02-16to2021-02-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-02-16to2021-02-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-02-16to2021-02-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-02-16to2021-02-16">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="From2021-02-16to2021-02-16">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-02-16to2021-02-16">HQY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-02-16to2021-02-16">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140367682810456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 16,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEALTHEQUITY,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001428336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2383166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15 West Scenic Pointe Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Draper<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HQY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "P?5%2M,.0858$  #?$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8;7/B-A#'7U\_A89V.NU,$EOB(=R5,$,(:9C+Y4@@S5P[?2%L 9K8DBO+
M(?GV71FPN=2LF;X)ENW]^Z?=U:Z4WEJ;YW0EA"6O<:32B\;*VN23YZ7!2L0\
M/=.)4/!DH4W,+0S-TDL3(WB8&\61QWR_X\5<JD:_E]^;F'Y/9S:22DP,2;,X
MYN;M4D1Z?=&@C=V-![E<67?#Z_<2OA1381^3B8&15ZB$,A8JE5H1(Q87C0']
M=,G:SB!_XP\IUNG>-7%3F6O][ ;C\*+A.R(1B< Z"0X_+V(HHL@I <<_6]%&
M\4UGN'^]4[_.)P^3F?-4#'7T)$.[NFAT&R04"YY%]D&O;\1V0CE@H*,T_TO6
MFW=;K08)LM3J>&L,!+%4FU_^NG7$O@$[8,"V!BSGWGPHI[SBEO=[1J^)<6^#
MFKO(IYI; YQ4+BI3:^"I!#O;'^H787J>!2EWPPNV9I<;,W; [%K,SPCMG!#F
M,_J]N0<$!08K,%BNU\0PR%^#>6H-!.IO1+)92#9SR=8!R2L=9) ^ELS>$E$U
M0]R\>_H9@6@5$"U490 $84YQ'?%E%05NO^!1*A".=L'1/LX9$V&D#LE(A03R
MI=(ON-(N\C]\^% 3^T[!UD$51\I*^T:N923(71;/J_,1U_!]>MKLM#M=A.>\
MX#D_AN=!+*7+1G#:'8\K/87KW(P&M[.;T?WC>/;MY.<?:<?_;7PW/$,(NP5A
M]QC"(034\(B,52A>R6?Q5L6(*_G@N!;K-IL=!.MC@?7Q&*P9?R7C$-CD0@8\
MK[V'PXHKMMDI:W:;M(/A4;^L=?XQ@&,5:)-HD[.=D*F%A4"T(4.=@4/!KSJL
M#'>-^M4(@]PKR/08R$$8&I&F)[L+<@OOD:^JF@R7I&WR)%)+IH%0,B 3+17,
M^,I /\20R^)-V?]'GJUU)3(N.<VD%9M%0WT?HRS[ <4K^GO*H1M!V&=ZK2H)
M:_J+X<G[G/Z>K&P2%*_R[\F*C)P8_2)54!US7/-QAJ&5?8/BY?X]VD2G%DK.
MGS(YO$QPQ6[+9VA R[Y!\:*?!W  >]'#*+A U\?Z%RT;!L4K_:T.P">3E598
M!ZL1.6?GIY#JJ&O*!D'QNOYDI+5"@6/B.%/;,IQ64N%"=1L06C8'BM?RJ8YD
M(*U42_(%TMM('E7RX"IU/*QL!@POUQ,C3@-PCX#UM=DGPE8--J%?%XOJ^-7H
MU9*5'8#AY?H_9.,TS8"L%A"7K07<VZSCQ7DF+>S5]()0]LO\5S(500;Y5KG]
MJ%%R^0G[ SCF!,\G).&&O/ H$^0G_\QM30A46)*NN$&YRP[ \)(],SQT^3=]
MB^>Z,OMJ!&[NOV$@9<%G>''>>8R,7H,55TMQ<(M9(W0WF%X-[C&FLM*SHRK]
M*!9FZ9ST.RC8E:L@"5?5L<4%#^:;MW=<=4?_+]Q],2616("0?W8.NF9SFMX,
MK$[R$^Q<6S@/YY<KP6$MN!?@^4)KNQNX0W'Q/XW^OU!+ P04    " "P?5%2
M@ZFE ]0!   R!@  #0   'AL+W-T>6QE<RYX;6S55=N*U$ 0_96F/\">1'9!
M20(J+ @J"SL/OG:22M+0-SN5,=FOMSN=V[@,J ^B+Y,ZIZI/G;Y.UN,DX:D#
M0#(JJ?N<=HCV+6-]U8'B_2MC0?M,8YSBZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9
M'M2#PIY49M"8TQ-E1=88O3.O:21\*5= +ESF] .7HG1BKN5*R"G2:2 J(XTC
MZ*U 3I/ ],\QG4047"XZ2FCC LEBA_A;+N4_)5;4>RBDW RF-!)%9CDB./W@
MP5P\DR]29(G/D_4.6\>G)+VC^X#YXYN4QM7@MC8)7:DBD] $.TZT7?BBL2PD
M$8WR02UX:S2?/:PCEL#+5B#E4]C"K\V5]MB0N!<?Z[ -)$QU#;VA)8PR$03]
MHUK4/LC>_9$LL>)B\/W@9Z-G_&TP"(\.&C'.>&RV_K?4D]OJW%HYO9.BU0KB
MW'^Y89'Q=1SIC!//OELX*94GP%%R 8>B.C+?';=G&'$]36-SVW/Z'WK^N^O<
M@@;'Y=&T/_K_\BK_CF.VW)[#%;VZH!M+PD.8TR_A?96[!U(.0J+0"^I$78-^
M<4^]//+2/^!7^KZ^AH8/$L];,J=[_!EJ,:@W6]5C6)>E:H\_A?<HN9\;[O\2
MQ0]02P,$%     @ L'U14I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2
MN6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>
M:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEF
MM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;
M&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ
M8K3^-8+)#^Q^ %!+ P04    " "P?5%2JL0B%C,!   B @  #P   'AL+W=O
M<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-
MKY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"
M/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4
M[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S
M8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,
MYU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8I
MGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>
MY0]02P,$%     @ L'U14B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW
M+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB
M688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:
MY$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?
M#'!X=/X!4$L#!!0    ( +!]45)ED'F2&0$  ,\#   3    6T-O;G1E;G1?
M5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS
M3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV
M(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U
M2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z
M6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1
M.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_
M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ L'U14@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "P?5%2@5TCL.\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "P?5%2F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +!]
M45*TPY!A5@0  -\0   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "P?5%2@ZFE ]0!   R!@  #0
M        @ &:#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +!]45*7BKL<
MP    !,"   +              "  9D.  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( +!]45*JQ"(6,P$  "("   /              "  8(/  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "P?5%2)!Z;HJT   #X 0  &@
M    @ 'B$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "P?5%299!YDAD!  #/ P  $P              @ ''$0  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   1$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm216328d3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://healthequity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm216328d3_8k.htm">tm216328d3_8k.htm</File>
    <File>hqy-20210216.xsd</File>
    <File>hqy-20210216_lab.xml</File>
    <File>hqy-20210216_pre.xml</File>
    <File>tm216328d3_ex1-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm216328d3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm216328d3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hqy-20210216_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hqy-20210216_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hqy-20210216.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hqy",
   "nsuri": "http://healthequity.com/20210216",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm216328d3_8k.htm",
      "contextRef": "From2021-02-16to2021-02-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://healthequity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm216328d3_8k.htm",
      "contextRef": "From2021-02-16to2021-02-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-21-024805-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-024805-xbrl.zip
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M^,=67ML30?>]:+24KND K)J &+*@&+%[ S&IY"&0LA28I8EJTGI1:4N=7Y(
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MIBH@1 !K ".E&BWF,_]]RQ+OYK&$-GE(BO?0>U@!]6Z1Z;'=) <0!P10MT.
M(QF$FE'^<9JSB(MG7GN=8L:WLDG<SW@,CUQZHMRB-:@(3< Z0P+";(A/ +9&
MZ(?BG1?$U1RB/ .D<O#(W44<R].5EO]<)XQ,P;-@U;IEK,-NDRR+,"">8'<
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MAIK7-/7I@V!JH$F3K#RL>1F>!R(5Z7]EIOI2__  L"%R/&ZV&#2&S35%$*2
MMJ!!<_W+"3Y7!MRN:!)=48[ANS(-C>/U -OVC*4 #X* .&B[@A8 S(4H5WJD
MX#-F3V+[G$7[.\$C0M0;76G5?O7=M1L8[9:<-Q6IR=2@T(!H>XM?@,-#%JB6
MQX=:'^;_%J!Z<5VM5<>CI\4CEJ?Q=INEJF>5]N#[Z)U!CA]0#"B \9BB(R(@
M  ?8A!Y9Y)$H#_V BF!4B_9Z#9<>5CHD\>?]/7D@0LV 6))=]ED>[JGC*F1
MK.LKO,'%,2_X>@.#0/&M;J'+P135,T K]29:F07Z766"\EQLWX:O[[J66W*W
MWB5_K7!*Y)[_ E!+ P04    " "P?5%2,). _UL'   \60  %    &AQ>2TR
M,#(Q,#(Q-E]P<F4N>&ULS9S;<MLV$(;O.]-W8)5K60<W;NW8S=B*E='$B5W+
M2=K>9"!R)6$, @H(6M+;%R E10<"7-]D[<G8"KD ]O\6 KD$P/.WBU1$3Z S
MKN1%HW/4;D0@8Y5P.;EH?!XV+X>]P: 198;)A DEX:(A5>/M7[_^$MF?\]^:
MS:C/021GT3L5-P=RK-Y$GU@*9]%[D*"94?I-](6)W!U1?2Y 1SV5S@08L"?*
MAL^BUT<G+&HV$=5^ 9DH_?E^L*EV:LSLK-6:S^='4CVQN=*/V5&L4EQ]0\-,
MGFTJ:R_:JY^R^+G@\O',_1JQ#")+2V9GBXQ?-+::G1\?*3UI==OM3NN?CS?#
M> HI:W+IJ,706)=RM525ZYR>GK:*LVO3 \O%2(MU&\>MM3N;FNU9'K#?\B3C
M9UGAWHV*F2F"7MM,Y+5P_VNNS9KN4+/3;1YWCA99TEC#+PAJ)> >QI'[:X.W
M:74*3)@I?,^Y6;J@M9Q!JZ=LE[3>%D6G&L;6_OO2-M#MV'\GKOI7.S9F.;,]
M,^.N8S6BUD[3,PT92%.HO;$'=HK PM@.!<FZ(M?\<YPSW+@"JS[3B9JN@^6I
M;<]^+"U7SJS=$2K>\4"X0*A]M=:!S'I0X,X@/IJHIU8"W&+OMMT'QZ+=;'=6
ML%_90]^*YBY'F=$L-NOZ!!N!*%KY9FWV3%H_S;<UE0=;;[5KNQ;[GFT'\5+'
MD=():,M]71?3\4[H#OOJRJ(U8]I6U(RG7&RB/M8J]3%:\5 >1[=QV29^)M-+
MZT7B/.D+-JF&NF>"I-JAP%JIAI;K.\ABS6>.3@W>'4LDY2XIY0IM)+#7WZ9[
MF'#GM7/(79/!'0R/%)XB2/S'E&-'4"UI'"ZES)FXAYG2-?AW+9'4?Z>D7J6-
M%/;?.=,&M%AB>!\8(Y&_ID3N44A*_4$SF7%'"8/]T!K)_83TYL2CD13\< I"
MN.R/252/K[)'PO^#$KY?YXO!?_WD[@'LA0<?@:TBR"#\^5*"<*"6- YWH+E*
M[&5?(R)P8(QD?TK)WJ/P!5"_E@F6^<84G371(]^31PJ\S[.8B=*OOCV6A:%7
MF&/!D^2KM3)? /Q_@6DT^BUC+'B2%+9&(@GV7J[UCDO!<<9OC05/DKS6B20A
M?RT--TLWL? I3T<_'LSN$C^TPI(F25A]H@@)KY]82./F34*4]RVQI$GRU) X
M0MH]JTHS,9 )+#[ ,H3[P!3+FR0_#<HC!'ZG><KT<LCC^F'DT!:+G"0K#0LD
M9/[ %H/$:N-C7LY%UJ/W%L%&@"0E1<DE#,1 QDK/U-;CZ)[*[3=TV5-)<*BO
M*8@-"DFN^@SIA*&Y3!(++5O]N>$2.J& 5)JCYZ/HPA"0^:+@=Y\'OXN'3Y+#
MULI\4?"/GP?_& ^?)(^ME4D/OV<_WNH'-??,?WN-L>!)\M@:B?38B^O0K;[3
MZHF7R[;JV!^4P : ,+T-BZ6/PNI& -/SUY98ZH2I;K4X>MIW*C-,_,=G=?><
MU?98\H1);T@HS4/+L@^XAQ^^!4Y[)EC*)'ENI1P:L"[:&IB_*^]:8+&2)*]5
M8DBHWB@WSS)5,OBD]] *2Y<D"_6)HAF0W6+HS#L8;)U&K[$C&6[W99# _*JY
ML7[T5)KF<O7$QS,/YS'%0B9)'8/R2( /E> Q-UQ./MH[2LV9J*9=98=%39(H
M^H61<+[3X*(.]F:]6&GF]D_HV_'8-R*'[+'<2?+$>J$O@?\@RW+0SXU"12EL
M+$A21JQHFI$'XMP.A\M.=_3@]@-YQIT#*RQQDG31)XJ$\"?UH)G;E#A<IB,E
M_!M>*@VQG$F2PX T$M0[WE1#WC/!XB7)"BOED(X2UXMXRN0$_.LHJBVQF$FR
MQ) XXC%Y@AJ3)\\<DTFR19\H4L+E"G?[';L="3YA_MURP0+H_4.4W -2:78J
M%AN:W'9VG1;>].V':O@>4RQVFBVA(7DTP/.$&TA*Q_I<,AG;=&RS@\^3W]>7
MPH:!9L\H4C3A),)7$.*#5',Y!)8I"4F9((3F$;Q%L+$@G+NLD4L8B"]*Y):5
M+A:O:L_WP6.*!4\X9^F11[E2M%R4O;DRE>\S"7'WE<#B)YR\#(LE74%GP'G.
MG^ =,VSE9R@*OA+8*!!.9(;%$N\"T#U[69JH\+S]GB&6.>'RW4IIA*B'*1/B
M*L^XA"PXVNP98E$3KM.ME$:(^CH%/;&#W7NMYF:ZVM$:0NXI@$5/N!HW*)4R
M!(L?^^G+G7Y!_A76Z'<U$,+WBJ1](4D<NX4=Y=5>)DQ[V(?LL?1)-Y+ZA9+P
MOS53T-MW6H5+ YOSA99?U)?"QH(DU<6*IKSR;KW7('CAW;'#4B=,:JN$4>X(
MRT>"QWVA6/ ^?L<,2YDP@ZV010CYBLE'G<],O+S3*@9P4S79YON'2*.0%6 #
M0YC;/@L%Y0,'E:9NJY2*'X=3*SV[S4WQ>ECK9?"Q0[ <-D"4FU81PDGOE+(?
MF]D@N5K>PQBT6S#Q  MS99M[#-\X(8ICHT3Z]B4TAHI@G;<.=-W8 ^Y%P.49
M]\N][-8>^1]02P,$%     @ L'U14F*N[.$:%   %VX  !$   !T;3(Q-C,R
M.&0S7SAK+FAT;>T]^U?BNM:_NY;_0S[NG;MT'7FT/'UQ%X.HC,\1U'%^<84V
M2+6TM4T%YJ__]DY:*% 4%1S/N7/..$B3['=V]MY).CO_[7=-\L1<S["MW822
MRB0(LS1;-ZR[W83/V\E2XK_EU96=#H=^T-?R=A,=SIVM=+K7ZZ5ZV93MWJ65
MS<W-=!_[)&2GK7YL/S634=(_3HX;6H=U:=*P/$XMC0T'F8;U,!L^M@Z[MES3
M&.N*3T(DV?04:&C51P.BG0MIV3C6E<=VS<NN/.QJ>'9.58K/T2%[# ?T9_55
MD&;@D/WX>G$\ZL[C^X^ZIKE++:]MNUW*08<(*9_,J$FU$ &2])@V!@B^I^[L
MIQ?AE))9)80SI9QQ3K&Y1;VAQ'4V(>X0)S3 "#63S"@1Z"YKSP1>2$-KV-'W
MDG>4.L/.;>JU1,>@(08VM+BVR;S8,:(E9I!F^Q9W!_$\!(TQPSR73Z.!AS%=
M.X\CZ!U&3=YAC[[!!RG-[F)W!?X4$F+V,:K#)\'_=KC!35;>2<M/:.TR3@G"
M2>+XI]U$U;8XLWBR.7! '9K\MIO@K,_3<I*F<5PZ +OS?\DDV3>8J6^1!N/;
MY)1VV1;IZ_UM4M\3O]QFU,W;R\87=>^@4CF'#^2&))/SCLYNW@*WMY-<WH9<
MO@)4;G\XZBW#\^HM PL$%N!/S0(A#JH@'9>:=4MG_2,VN,V E\JII6SV57 W
M(W K76;I\,/W37IWVZ:FQUX!JO 51+UWJ]P&SD/"A$>O@:'>-CK49=ZM>BM\
MI03BB6>O@;.'M)P'L+)3),T$WK+U ?'XP&2[B398X!91,@XG3:,+74Y9CUS8
M76IMR <;0(!KM(6MZ\93.$XW/,>D@RUBV183C49_"XV6N6(VB*^&KC,KF!SX
M /J>^ET ITG+[_,+="W[KMU%<T'?J!2X/?H]02Q@'+ Q8RO6(!+ED47LI,=0
MO ^O]+:["?#06RT;_!"UA*U$*1HSI419M,\@(CTN#B0*_"9S84%G7M@)W?26
M)]9?H(^(176K([WOXR 9SJA4W],302L'-[*;\(RN8S+I.H;H)N!+E)[MNQ&,
MPD*V ID00W]6)J&7"X<QH9#AT^%S0\>6ML%<(IAAL<M;M7XTKKS)P2-TZ5A\
M 38'Q&SKTU1 C.'R/<I9><1""&G4-C4,-#IC4-@R2=88 >'#0*3C<O8M0PH9
M)N>4-+N,>K[+RL$LWH(^(;"P:1P%0IL!7[J$F2@"(8A.;\8Q<CU3>,!-@!JG
M98MCQ;R@W'8CS:^7P22-<5 C2/>897<-ZR6T+\ME$F\<X+!]3 IQ DU/S4CI
M)D(GNI,&$/")_^\XH>/M4O?.L+9()@%QAE,>;T1OGFS3KF&"9W[6GV\3"2C)
M;0> .7SXH&5S;G?%LT3Y/_]2"IGM#T T1!%9^2Y\DR7/Z9U8H*.+3Q2BHL:
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MC?U&K:X%MK:! 9OI8R9-P.((2G:#4$LG368R!XE>79%D1[NB$H*^HDH=EE/
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M0IS(3C1.?9)3\X$U\_$M8=P)7E.*I+I_0=0L*$+-KX_2X:4DP_\,FUV(53;
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M(1^(65VAIF>3.RP^L1CB+6([HM(4H9_X#I'V@3X/6V':%?-OHF5U)22&>=S
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M2>=YHO@V(@@)7\$G9=I@];!(18DH$G4?^ AJMNM*]WNE(\-=G'>P]/UK03A
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MC'*ER1'\<UG<H9_^5.;4L4%GFA5UN<1D9W8V7S'P5-5P!%' 2HP4L5GM6'Q
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M,64"LS 5%]2?UD"#,8<M:VH)R-*E#1^&\AQX+6+%9;6O*P^2(GT9G!XD-5@
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M0(Q(.T0F2WAD))SB(5R33/S<V7H&BB#[P4P6B;+!,R6Z<+:NR"NL?MH_*J?
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M#^%'?,EKVC7U\GL7!:4=B$].C0#CLI ;!=>;X*1&^H-1L].D6N22IT/6D<_
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M'[/).+=M@!4# >/SW 3$F("<J&WV 8E -/FVP1(6X>TS7^>$"K9019Z8)!V
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MH#]B[%$OT8$$K)XB\[Y;K-6T@)%E8O9P&(S!?N&F%JJ3C31(Z''U(1ILH)5
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M0<106@Z] ;05F( CW]7:[XGY?0E]3A_3O3355N/!/>O+NXA6:?<S?=@_T(0
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MS0ULKX; 82K_MDLT,N&LEXZP!^*44\#N7/$'YDI=ABXB4<O;Z!*:0PDQO3.
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M^.E<YM.NT83ZP@;=M3+6U-),FP?LX,]'GT_^I+,\O_YX 7_Y?U!+ 0(4 Q0
M   ( +!]45)&(_EO0P,  )D,   0              "  0    !H<7DM,C R
M,3 R,38N>'-D4$L! A0#%     @ L'U14I56":S^"@  X(<  !0
M     ( !<0,  &AQ>2TR,#(Q,#(Q-E]L86(N>&UL4$L! A0#%     @ L'U1
M4C"3@/];!P  /%D  !0              ( !H0X  &AQ>2TR,#(Q,#(Q-E]P
M<F4N>&UL4$L! A0#%     @ L'U14F*N[.$:%   %VX  !$
M ( !+A8  '1M,C$V,S(X9#-?.&LN:'1M4$L! A0#%     @ L'U14E^I44^&
MG0  YY(# !0              ( !=RH  '1M,C$V,S(X9#-?97@Q+3$N:'1M
64$L%!@     %  4 0P$  "_(      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
